Literature DB >> 10644890

Induction of Fas and Fas-ligand expression in plasmacytoma cells by a cytotoxic factor secreted by murine macrophages.

C Y Chu1, J Tseng.   

Abstract

Induction of tumoricidal activity is one of the major functions of activated macrophages. Our previous study demonstrated that P388D1 murine macrophage-like cells secreted a plasmacytoma cytotoxic factor (PCF) that selectively killed certain tumor cell lines including MOPC-315 plasmacytoma in vitro. Our subsequent studies demonstrated that PCF killed MOPC-315 cells by induction of apoptosis. In this report, the involvement of Fas and Fas ligand (FasL) in PCF-induced apoptosis was investigated. Results suggest that expression of Fas mRNA time-dependently increased in PCF-treated cells and reached an optimal level after 36 h of treatment. The augmented effect of PCF on Fas mRNA expression was significantly reduced by the addition of CB7.C2, an anti-PCF monoclonal antibody. The expression of FasL mRNA was also induced by PCF and reached an optimal level at 24 h, but sharply decreased after 36 h of treatment. Caspase-3 is one of the proteolytic enzymes that can be activated by the Fas-FasL interaction. In our studies, the enzymatic activity of caspase-3 was significantly induced by PCF after 6 h of treatment and reached an optimal level at 12 h. The augmented effect of PCF on caspase activity was significantly reduced by the addition of CB7.C2 and the caspase-3-specific inhibitor, DEVD-fmk. Therefore, PCF-treated plasmacytoma cells might undergo apoptosis via interaction between Fas and FasL. Copyright 2000 National Science Council, ROC and S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10644890     DOI: 10.1007/bf02255919

Source DB:  PubMed          Journal:  J Biomed Sci        ISSN: 1021-7770            Impact factor:   8.410


  5 in total

1.  Skin-stage schistosomula of Schistosoma mansoni produce an apoptosis-inducing factor that can cause apoptosis of T cells.

Authors:  Lin Chen; Kakuturu V N Rao; Yi-Xun He; Kalyanasundaram Ramaswamy
Journal:  J Biol Chem       Date:  2002-07-09       Impact factor: 5.157

2.  Intermittent metronomic drug schedule is essential for activating antitumor innate immunity and tumor xenograft regression.

Authors:  Chong-Sheng Chen; Joshua C Doloff; David J Waxman
Journal:  Neoplasia       Date:  2014-01       Impact factor: 5.715

3.  VEGF receptor inhibitors block the ability of metronomically dosed cyclophosphamide to activate innate immunity-induced tumor regression.

Authors:  Joshua C Doloff; David J Waxman
Journal:  Cancer Res       Date:  2012-01-11       Impact factor: 12.701

4.  Transcriptional profiling provides insights into metronomic cyclophosphamide-activated, innate immune-dependent regression of brain tumor xenografts.

Authors:  Joshua C Doloff; David J Waxman
Journal:  BMC Cancer       Date:  2015-05-08       Impact factor: 4.430

5.  Anti-tumor innate immunity activated by intermittent metronomic cyclophosphamide treatment of 9L brain tumor xenografts is preserved by anti-angiogenic drugs that spare VEGF receptor 2.

Authors:  Joshua C Doloff; Chong-Sheng Chen; David J Waxman
Journal:  Mol Cancer       Date:  2014-06-26       Impact factor: 27.401

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.